title: Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma.
abstract: Melanoma inhibitory activity (MIA) was originally identified as an 11 kDa protein secreted from malignant melanoma cells. We have shown that MIA is strongly expressed in melanoma and melanoma cell lines but not in melanocytes and normal skin. We also observed that MIA mRNA expression correlates with progressive malignancy of melanocytic tumors. Measuring MIA in serum or plasma by a sensitive and quantitative ELISA and investigating the potential of MIA serum levels as a novel marker for malignant melanomas showed that the protein can be used to monitor therapy and follow-up. The present study measured the variations in blood concentrations of MIA in 84 patients with stage II-IV melanoma by ELISA. Patients treated with repeated injections of a polyvalent melanoma vaccine (PMV), interferon-alpha-2b (IFN-alpha 2b) or interleukin-2 (IL-2) were followed during treatment duration. Before treatment, patients treated with PMV or IFN-alpha 2b had comparable low MIA concentrations, whereas most IL-2-treated patients had higher MIA levels. At the end of treatment, MIA concentrations were higher in patients with progressive disease (PD) than in patients with no clinical evidence of melanoma (NPD) for PMV, IFN-alpha 2b or IL-2 therapy (3.7 +/- 0.2 vs 11.5 +/- 5.4 ng/ml, 3.8 +/- 0.2 vs 8.3 +/- 1.7 ng/ml, and 2.3 +/- 0.7 vs 20.2 +/- 7.4 ng/ml, respectively, p < 0.05). In contrast to the stable MIA concentrations measured in NPD patients, significant increase in MIA levels were observed in PD patients over time regardless of treatment. For PMV- and IFN-alpha 2b-treated patients, a rise in MIA levels occurred significantly earlier than clinical diagnosis of melanoma recurrence. In conclusion, our data suggest that quantitation of MIA serum levels may be used for detection of both clinically apparent and non-apparent metastatic melanoma disease and for monitoring therapy.
authors.affiliation: Institute of Pathology, RWTH-Aachen, Germany.
authors.forename: A K
authors.initials: AK
authors.lastname: Bosserhoff
authors.forename: D
authors.initials: D
authors.lastname: Dreau
authors.forename: R
authors.initials: R
authors.lastname: Hein
authors.forename: M
authors.initials: M
authors.lastname: Landthaler
authors.forename: W D
authors.initials: WD
authors.lastname: Holder
authors.forename: R
authors.initials: R
authors.lastname: Buettner
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D019496:Cancer Vaccines / Q000627:therapeutic use; D006224:Cricetinae; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D016326:Extracellular Matrix Proteins; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000097:blood* / Q000175:diagnosis / Q000628:therapy; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood*; D009364:Neoplasm Recurrence, Local / Q000097:blood; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000628:therapy; D017778:Vaccines, Combined
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D019496:Cancer Vaccines; D016326:Extracellular Matrix Proteins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; C090059:MIA protein, human; D009363:Neoplasm Proteins; D011994:Recombinant Proteins; D017778:Vaccines, Combined; C094534:polyvalent melanoma cell vaccine